PharmaTher Holdings Ltd. today announced it submitted an Investigational New Drug application with the U.S. Food and Drug Administration for the initiation of a Phase 2 clinical trial to evaluate the safety, efficacy and pharmacokinetics of low-dose ketamine in the treatment of levodopa-induced dyskinesia in patients with Parkinson’s disease.